1.30

7.57% -0.1065

After Hours: 1.39 0.09 +6.92%

Estrella Immunopharma Inc (ESLA)

Overview News Price History Discussions Forecast

Estrella Immunopharma Inc stock is traded at $1.30, with a volume of 51,496. It is down -7.57% in the last 24 hours and down -4.41% over the past month. Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.

Previous Close:

$1.4065

Open:

$1.31

24h Volume:

51,496

Relative Volume:

0.27

Market Cap:

$55.46M

Revenue:

Net Income/Loss:

$-13.06M

P/E Ratio:

-3.6404

EPS:

-0.3571

Net Cash Flow:

$-1.79M

1W Performance:

-11.56%

1M Performance:

-4.41%

6M Performance:

-52.90%

1Y Performance:

+17.15%

1-Day Range:

$1.30

$1.4599

1-Week Range:

$1.30

$1.80

52-Week Range:

$0.78

$3.15

Estrella Immunopharma Inc Stock (ESLA) Company Profile

Name

Estrella Immunopharma Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

(510) 318-9098

Address

5858 HORTON STREET, SUITE 370, EMERYVILLE

Employee

Twitter

Next Earnings Date

2026-05-13

Latest SEC Filings

ESLA's Discussions on Twitter

Compare ESLA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ESLA Estrella Immunopharma Inc	1.30	60.01M	0	-13.06M	-1.79M	-0.3571
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Estrella Immunopharma Inc Stock (ESLA) Latest News

May 05, 2026

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference - Business Wire

May 05, 2026

May 01, 2026

Is Estrella (ESLAW) stock a safe investment |Cash Flow - Newser

May 01, 2026

Apr 30, 2026

Eureka-led Estrella (NASDAQ: ESLA) details 59.3% control and board pay - Stock Titan

Apr 30, 2026

Apr 29, 2026

Estrella Immunopharma CFO Xu Jiandong buys $2,594 in stock - Investing.com

Apr 29, 2026

Estrella Immunopharma CFO Xu Jiandong buys $2,594 in stock By Investing.com - Investing.com Canada

Apr 29, 2026

Estrella Immunopharma (ESLA) CFO boosts stake with small share buys - Stock Titan

Apr 29, 2026

ESLA Estrella Immunopharma falls 3.92% after Q1 2026 EPS misses analyst forecasts by a wide 90.6% margin.Growth Phase - Newser

Apr 29, 2026

Apr 27, 2026

Is Estrella (ESLAW) stock a good option for investors |High Volatility - Newser

Apr 27, 2026

Estrella Immunopharma (ESLA) Stock: Changing Trend? (Institutional Selling) 2026-04-27Social Trading - Newser

Apr 27, 2026

Apr 26, 2026

Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Declines By 57.6% - MarketBeat

Apr 26, 2026

Apr 24, 2026

OneIM Acquisition Corp. (OIM) - Minichart

Apr 24, 2026

Apr 22, 2026

Estrella Immunopharma (ESLA) Management Strategy | Q1 2026: Below ExpectationsStrong Sell - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 22, 2026

Apr 21, 2026

Robinson Opportunistic Income Fund's Estrella Immunopharma Inc(ESLAW) Holding History - GuruFocus

Apr 21, 2026

Apr 20, 2026

Estrella Immunopharma (ESLA) Stock Dividend Yield (Drifts Lower) 2026-04-20Most Discussed Stocks - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026

Apr 18, 2026

ESLA (Estrella Immunopharma Inc.) reports wider than expected Q1 2026 EPS loss but shares rise 13 percent in regular trading.CFO Commentary - Newser

Apr 18, 2026

Apr 16, 2026